| Literature DB >> 29149611 |
Robert B Conley1, Dane Dickson2, Jean Claude Zenklusen3, Jennifer Al Naber1, Donna A Messner1, Ajlan Atasoy4, Lena Chaihorsky5, Deborah Collyar6, Carolyn Compton7, Martin Ferguson3, Sean Khozin8, Roger D Klein9, Sri Kotte10, Razelle Kurzrock11, C Jimmy Lin10, Frank Liu12, Ingrid Marino13, Robert McDonough14, Amy McNeal15, Vincent Miller13, Richard L Schilsky16, Lisa I Wang17.
Abstract
The Center for Medical Technology Policy and the Molecular Evidence Development Consortium gathered a diverse group of more than 50 stakeholders to develop consensus on a core set of data elements and values essential to understanding the clinical utility of molecularly targeted therapies in oncology.Entities:
Mesh:
Year: 2017 PMID: 29149611 DOI: 10.1016/j.cell.2017.10.032
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582